Sustained-release dosage forms of ruxolitinib
US10874616B2 · kind B2 · utility
15Cited by
84References
36Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 14, 2018 |
| Grant date | Dec 29, 2020 |
| Priority date | — |
| Expiry date | Nov 14, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.